Beyond Meat's IPO leads to a rare 2000-style stock surge

Beyond Meat Inc.’s first day of trading after its initial public offering brought the kind of stock surge that has been relatively rare since 2000, the year that an Internet-driven bull market ended. The producer of vegan beef and sausage substitutes soared 163 percent in its debut. Beyond Meat is only the eighth U.S. company in the past 18 years to climb at least 125 percent after completing an initial public offering of $100 million or more, according to data compiled by Bloomberg. The rest are shown in the chart. There were 29 in 2000 alone.

 

Aduro BioTech (ADRO) began trading on the NASDAQ on 15 April 2015

• Aduro Biotech merged with Chinook Therapeutics. The combined company operates as Chinook Therapeutics. (2020)

Description

Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live, attenuated Listeria, GVAX and cyclic dinucleotides (CDNs). Aduro’s lead program is an immunotherapy regimen combining Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy. Its pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX. CRS-207 is based on Aduro’s Listeria platform. ADU-623 is Aduro's first clinical bivalent Listeria-based immunotherapy. ADU-214 is a bivalent Listeria-based immunotherapy that targets both mesothelin and an EGFR mutation. CDNs are small molecules that signal through STING and induce a potent immune response. STINGVAX is the combination of CDNs and GVAX.

Address

626 Bancroft Way Ste 3-C
BERKELEY, CA 94710-2224
United States

Website 

http://www.adurobiotech.com

Key stats and ratios

	Q4 (Dec '14)	2014
Net profit margin	-9.30%	-127.07%
Operating margin	-11.38%	-142.79%
EBITD margin	-	-141.00%
Return on average assets	-4.39%	-24.96%
Return on average equity	-7.19%	-47.17%
Employees	50